Global Chronic Spontaneous Urticaria Market to Reach $3.08 Billion by 2029, Growing at 8.4% CAGR

What industry-specific factors are fueling the growth of the chronic spontaneous urticaria market?
The chronic spontaneous urticaria market is expected to grow due to an increase in alcohol consumption. The factors contributing to the surge in alcohol consumption include social customs, stress, advertising, affordability, and accessibility. In some people, drinking alcohol can worsen chronic spontaneous urticaria symptoms, leading to an increase in hives and swelling. For example, rehabs.UK, a UK service providing support and advice for addiction recovery, reported in February 2024 that 55% of men and 41% of women have weekly alcohol consumption. Additionally, daily alcohol intake was reported by 8% of men and 5% of women. Between 2021 and 2022, there were 342,795 hospital admissions solely due to alcohol, equating to 626 admissions per 100,000 people. Thus, the rise in alcohol consumption is fueling the expansion of the chronic spontaneous urticaria market.

Get Your Chronic Spontaneous Urticaria Market Report Here:
https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

What Is the projected market size and growth rate for the chronic spontaneous urticaria market?
The market size of chronic spontaneous urticaria has seen significant growth in the past few years. With a compound annual growth rate (CAGR) of 8.6%, it is projected to expand from $2.06 billion in 2024 to $2.23 billion in 2025. The notable growth during the historic period is a result of factors such as enhanced diagnostic tools, heightened awareness in healthcare sectors, patient advocacy and supportive groups, continued research and clinical trials searching for novel therapies, and a rise in healthcare spending.

There is an anticipation of considerable expansion in the market for chronic spontaneous urticaria in the upcoming years. The projection is a surge to $3.08 billion in 2029, compounded annually at a rate of 8.4%. Factors contributing to this projected growth range from an increase in diagnosed CSU cases and an expanding patient base, to advancements in healthcare infrastructure and favorable regulations promoting patient-focused care models. Moreover, economic progression in emerging markets plays a key role. Significant trends for the forecasted period encompass technological breakthroughs, progression in biological therapies, tailored medicine, the advent of telemedicine and digital health, improved diagnostic tools, the incorporation of AI and machine learning and a rising number of drug approvals and releases.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

What new trends are reshaping the chronic spontaneous urticaria market and its opportunities?
Key players in the chronic spontaneous urticaria market are in the process of producing superior Briquilimab (JSP191) to augment treatment productivity and lessen the frequency of dosages. Briquilimab (JSP191) is a type of monoclonal antibody developed to isolate and diminish particular immune cells, particularly those that target CD47 in conditions like chronic spontaneous urticaria. For example, in November 2023, Jasper Therapeutics Inc., a biotechnology firm in the clinical stage based in the US, declared it has administered its initial dosage to a patient in a Phase 1b/2a clinical trial of Briquilimab for chronic spontaneous urticaria (CSU). This milestone is significant in evaluating the safety and efficacy of Briquilimab, a novel monoclonal antibody that aims at CD47 for treating this recurring condition of hives and itchiness. The trial's goal is to determine the extent to which Briquilimab can relieve symptoms and enhance the life quality of CSU patients.

What major market segments define the scope and growth of the chronic spontaneous urticaria market?
The chronic spontaneous urticaria market covered in this report is segmented -

1) By Treatment: Medication, Phototherapy, Other Treatments
2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration
3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)
2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy
3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the chronic spontaneous urticaria industry growth?
Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

What Is Covered In The Chronic Spontaneous Urticaria Global Market Report?

•Market Size Forecast: Examine the chronic spontaneous urticaria market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the chronic spontaneous urticaria market for a structured understanding.
•Key Players Overview: Analyze major players in the chronic spontaneous urticaria market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the chronic spontaneous urticaria market.
•Segment Contributions: Evaluate how different segments drive overall growth in the chronic spontaneous urticaria market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the chronic spontaneous urticaria market.
•Industry Challenges: Identify potential risks and obstacles affecting the chronic spontaneous urticaria market.
•Competitive Landscape: Review strategic developments in the chronic spontaneous urticaria market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.